drugset

drugset / Trial / NCT07049575

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

NCT07049575 ↗

Phase 1 Recruiting 24 enrolled Incyte Corporation

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Timeline

Start: 2025-11-03
Primary completion: 2026-12-09
Completion: 2026-12-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	1.5 %	Topical

Indications